Hombrechtikon, Switzerland
PreComb, founded in 2018, stands at the nexus of biotechnology and artificial intelligence with its offering of AI-guided Functional Precision Medicine. The privately held Swiss company, PreCombTherapeutics AG, is innovating in the space of in vitro cancer diagnostics, aimed at enhancing cancer management.
At the core of PreComb's value proposition is its 3DTwin™ technology. This automated, microtumor-based system enables clinical institutions to seamlessly integrate and implement precision medicine on-site. By allowing the functional evaluation of various cancer drugs, combinations, and concentrations on patient-derived micro-tumors, PreComb maximizes treatment outcomes, offering a promising prospect for healthcare systems aiming for tailored patient care.
The company's recent expansion in its financial backing, marked by a Series A investment on 01 December 2024, with prominent contributors like SICTIC and Koodos, underscores its potential to further revolutionize the cancer diagnostics landscape.
